ASCO 2022 Conference Coverage

 

ASCO 2022 Conference Coverage
P

ASCO 2022 Using cfDNA to Identify Guideline-Relevant Biomarkers for Therapy Selection in 14,000 Pts With mCRC

By ASCO 2022 Conference Coverage FEATURING Pashtoon Kasi
By ASCO 2022 Conference Coverage FEATURING Pashtoon Kasi
210 views
June 15, 2022
0 Comments
Login to view comments. Click here to Login
GI
10:11
ASCO 2022 Conference Coverage

ASCO 2022 on Atezolizumab + Bevacizumab vs Lenvatinib or Sorafenib i…

Feat. M. Rimini
07:56
ASCO 2022 Conference Coverage

ASCO 2022 on RAS Co-Mutation and Early Onset Disease Represent an Ag…

Feat. B. Johnson
03:33
ASCO 2022 Conference Coverage

ASCO 2022 Patient-Reported Outcomes From the Phase 3 HIMALAYA Study …

Feat. P. Galle
02:15
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Adjuvant Chemotherapy Guided by ctDNA An…

Feat. J. Tie
07:51
ASCO 2022 Conference Coverage

Updates on the PARADIGM Trial: PAN + mFOLFOX6 vs. BEV + mFOLFOX6 as …

Feat. T. Yoshino
01:21
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Phase 3 CAIRO5 Study: FOLFOXIRI + Bev…

Feat. C. Punt
07:57
ASCO 2022 Conference Coverage

ASCO 2022 on Phase I/II Trial of Encorafenib, Cetuximab, & Nivol…

Feat. V. Morris
59
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Phase I/II Trial of Encorafenib, Cetu…

Feat. V. Morris
07:35
ASCO 2022 Conference Coverage

ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study o…

Feat. A. Ruth He, F. Banovac
40
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on an Open-Label, Multicenter, Randomize…

Feat. A. Ruth He, F. Banovac
58
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on EA2183: A Phase III Study of Consolid…

Feat. N. Uboha
06:44
ASCO 2022 Conference Coverage

ASCO 2022 on EA2183: A Phase III Study of Consolidative RT in Patien…

Feat. N. Uboha
05:40
ASCO 2022 Conference Coverage

ASCO 2022 Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant…

Feat. D. Takahari
11:07
ASCO 2022 Conference Coverage

ASCO 2022 The Differential Response to Immune Checkpoint Inhibitors …

Feat. M. Khushman
06:33
ASCO 2022 Conference Coverage

ASCO 2022 Testing of a Machine Learning Model for Ability to Predict…

Feat. M. Sun
05:53
ASCO 2022 Conference Coverage

ASCO 2022 on a Regional Subgroup Analysis of the Phase 3 TOPAZ-1 Stu…

Feat. A. Vogel
04:54
ASCO 2022 Conference Coverage

ASCO 2022 IMMUTACE - A Biomarker-Orientated Phase II, Single-Arm, Op…

Feat. A. Vogel
05:30
ASCO 2022 Conference Coverage

ASCO 2022 on SWOG S2012: Randomized Phase II/III Trial of 1L Platinu…

Feat. D. Bing Zhen
05:12
ASCO 2022 Conference Coverage

ASCO 2022 IMMUNIB Trial: A Single-Arm, Phase II Study Evaluating Saf…

Feat. A. Vogel
10:29
ASCO 2022 Conference Coverage

ASCO 2022 Using cfDNA to Identify Guideline-Relevant Biomarkers for …

Feat. P. Kasi
58
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Targeting HER2 Mutation-Positive Advance…

Feat. J. Harding
54
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on ctDNA Profile in Pancreatic Ductal Ad…

Feat. F. Esposito
09:42
ASCO 2022 Conference Coverage

ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Ca…

Feat. J. Harding
05:39
ASCO 2022 Conference Coverage

ASCO 2022 on ctDNA Profile in Pancreatic Ductal Adenocarcinoma and P…

Feat. F. Esposito
04:22
ASCO 2022 Conference Coverage

ASCO 2022 on the Multicenter Phase Ib US Trial of Salvage CT041 CLDN…

Feat. G. Botta
01:26
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Multicenter Phase Ib US Trial of …

Feat. G. Botta
01:13
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Investigating a Switch Maintenance Co…

Feat. S. Stintzing
55
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Perioperative Ramucirumab + FLOT vs. …

Feat. T. Oliver Götze
07:37
ASCO 2022 Conference Coverage

ASCO 2022 on Investigating a Switch Maintenance Concept With 5-FU + …

Feat. S. Stintzing
08:49
ASCO 2022 Conference Coverage

ASCO 2022 on the Phase 2/3 Study of an Individualized Neoantigen Vac…

Feat. J. Hecht
34
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Phase 2/3 Study of an Individuali…

Feat. J. Hecht
06:16
ASCO 2022 Conference Coverage

ASCO 2022 on NSABP FC-10: A Phase Ib Study of Pembro + Pemetrexed &a…

Feat. J. Krauss
34
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on mFOLFOXIRI + PAN vs. mFOLFOX6/PAN as …

Feat. C. Cremolini
11:34
ASCO 2022 Conference Coverage

ASCO 2022 on mFOLFOXIRI + PAN vs. mFOLFOX6/PAN as Initial Treatment …

Feat. C. Cremolini
09:20
ASCO 2022 Conference Coverage

ASCO 2022 on the Comparative Efficacy of Novel Combination IO Strate…

Feat. C. Fulgenzi
40
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Multicenter Phase II Study of Abemaci…

Feat. R. Kelly
05:15
ASCO 2022 Conference Coverage

ASCO 2022 on Multicenter Phase II Study of Abemaciclib & Ramucir…

Feat. R. Kelly
31
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 NEOPRISM CRC: Neoadjuvant Pembrolizumab …

Feat. K. Shiu
15:40
ASCO 2022 Conference Coverage

ASCO 2022 NEOPRISM CRC: Neoadjuvant Pembrolizumab Stratified to Tumo…

Feat. K. Shiu
01:02
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Pembrolizumab + mFOLFOX7/FOLFIRI for …

Feat. R. Kim
08:41
ASCO 2022 Conference Coverage

ASCO 2022 on KEYNOTE-651: Pembrolizumab + mFOLFOX7/FOLFIRI for mCRC:…

Feat. R. Kim
43
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (C…

Feat. M. Overman
04:11
ASCO 2022 Conference Coverage

ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Stu…

Feat. M. Overman
39
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Immunotherapy With Nivolumab After Progr…

Feat. A. Rauthan
09:02
ASCO 2022 Conference Coverage

ASCO 2022 Immunotherapy With Nivolumab After Progression on Lenvatin…

Feat. A. Rauthan
23
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updates on Infigratinib vs. Gemcitabine …

Feat. G. Abou-Alfa
06:42
ASCO 2022 Conference Coverage

ASCO 2022 on PROOF 301 Trial: Updates on Infigratinib vs. Gemcitabin…

Feat. G. Abou-Alfa